Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus for Improving Social Abilities in PHTS
NCT07218575Phase 3Not yet recruiting
- Sponsor
- Boston Children's Hospital
- Start
- Sep 2026
- Primary completion
- Sep 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in PTEN hamartoma tumor syndrome (PHTS) comparing Everolimus with Placebo (2 arms). Primary endpoint: Social Responsiveness Scale at 6 months. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
everolimus
03
Conditions
PTEN hamartoma tumor syndrome (PHTS)
Beyond the preview
Go deeper on NCT07218575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07218575.